Physician profile
Jonathan Freese
NPI 1194381186
$4,415.06
in general payments reported to CMS, 2019-2025
44 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.76 · 2022: $487 · 2023: $1,829 · 2024: $677 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.67 |
| Education | $307.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $378.97 | 2021-2025 | Tagrisso, Imfinzi |
| Eisai INC. | $318.50 | 2022-2025 | |
| Seagen INC. | $305.67 | 2023 | Padcev, Tukysa, Adcetris |
| Astellas Pharma US INC | $211.06 | 2023-2025 | Vyloy, Xospata, Padcev |
| Daiichi Sankyo INC. | $200.34 | 2022-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $190.92 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $190.53 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $182.66 | 2023-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $161.58 | 2022-2023 | Opdivo, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $160.79 | 2023-2025 | |
| Beigene USA, INC. | $145.41 | 2024 | Brukinsa |
| Novocure INC. | $128.67 | 2025 | Optune Lua (Novottf-200t) |
| Janssen Biotech, INC. | $128.07 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Gilead Sciences, INC. | $114.84 | 2023-2025 | Trodelvy |
| Exelixis INC. | $109.76 | 2023-2024 | Cabometyx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $107.15 | 2023 | |
| Glaxosmithkline, LLC. | $106.53 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $105.75 | 2022-2025 | Jaypirca, Retevmo, Verzenio |
| Aveo Pharmaceuticals, INC. | $103.03 | 2023-2024 | Fotivda |
| Sanofi-Aventis U.S. LLC | $95.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.07 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $84.39 | 2024-2025 | Ultomiris |
| Tersera Therapeutics LLC | $77.65 | 2022-2023 | Zoladex, Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $73.04 | 2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $72.54 | 2025 | Iclusig, Alunbrig |
| Genmab U.S., INC. | $57.30 | 2025 | Epkinly |
| Pharmaessentia USA Corporation | $50.73 | 2024-2025 | Besremi |
| Beone Medicines USA, INC. | $47.79 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $46.47 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Genzyme Corporation | $39.94 | 2023 | |
| Geron Corporation | $37.67 | 2025 | Rytelo |
| Legend Biotech USA INC. | $37.08 | 2025 | Carvykti |
| Abbvie INC. | $32.19 | 2022 | |
| Mirati Therapeutics, INC. | $30.64 | 2023 | Krazati |
| Avyxa Pharma, LLC | $28.01 | 2025 | |
| Emd Serono, INC. | $24.48 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.97 | 2025 | |
| Jazz Pharmaceuticals INC. | $21.42 | 2023 | |
| Fennec Pharmaceuticals, INC. | $21.03 | 2025 | Fyarro |
| Adc Therapeutics America, INC. | $16.23 | 2022 | |
| Pfizer INC. | $15.08 | 2023 | |
| Genentech USA, INC. | $14.53 | 2025 | Tecentriq |
| Amgen INC. | $14.50 | 2023 | Vectibix, Xgeva, Nplate |
| Celgene Corporation | $13.08 | 2023 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Freese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.